Is Baricitinib available in hospitals?

Baricitinib is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis, particularly those who have failed to respond to or are intolerant to traditional disease-modifying antirheumatic drugs (DMARDs) such as methotrexate (Methotrexate). In addition, baricitinib can also be used to treat related diseases such as rheumatoid arthritis and psoriatic arthritis.

Baricitinib has been launched in China and is included in medical insurance. Patients can purchase it domestically. Due to different medical insurance reimbursement policies in different regions, the reimbursement ratio is also different. The price is about 1200~1600 yuan. For specific prices, please consult the local pharmacy or the medical insurance bureau. Baricitinib has both original and generic drugs abroad. The original drug is mainly Eli Lilly’s original drug, and its price is higher than in China. Generic drugs are mainly Bangladeshi generic drugs, and the price is around 450 yuan. The ingredients of original drugs and generic drugs are basically the same.

In clinical studies, baricitinib has shown significant efficacy in reducing arthritis symptoms, improving joint function, reducing pain, and improving quality of life. It is often used in combination with other treatments, such as nonsteroidal anti-inflammatory drugs or DMARDs, to achieve optimal results.

However, baricitinib may also cause some side effects, including infection, skin reactions, nausea, diarrhea, headache, high blood pressure, etc. Some side effects may be serious, such as increased risk of infection due to immunosuppression, increased risk of deep vein thrombosis and pulmonary embolism, cardiovascular events, etc. Therefore, before using baricitinib, you should consult your doctor about the potential risks and benefits, and use and monitor it as recommended by your doctor.